Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges
出版年份 2011 全文链接
标题
Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges
作者
关键词
-
出版物
Current Atherosclerosis Reports
Volume 14, Issue 1, Pages 1-10
出版商
Springer Nature
发表日期
2011-11-18
DOI
10.1007/s11883-011-0219-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Meta-analysis: Statin Therapy Does Not Alter the Association Between Low Levels of High-Density Lipoprotein Cholesterol and Increased Cardiovascular Risk
- (2013) Haseeb Jafri et al. ANNALS OF INTERNAL MEDICINE
- Anacetrapib and Dalcetrapib: Two Novel Cholesteryl Ester Transfer Protein Inhibitors
- (2011) Marta A Miyares ANNALS OF PHARMACOTHERAPY
- Apolipoprotein A-I Therapy
- (2011) Michael H. Davidson JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis
- (2011) Amit V. Khera et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective
- (2010) Marshall Elam et al. CURRENT OPINION IN LIPIDOLOGY
- RETRACTED: Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients by Lipid and Nonlipid Biomarkers
- (2010) Benoit J. Arsenault et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial
- (2010) Paul M Ridker et al. LANCET
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome
- (2009) Gregory G. Schwartz et al. AMERICAN HEART JOURNAL
- Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes
- (2009) Kausik K. Ray et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Association between dyslipidemia and vascular events in patients treated with statins: Report from the UK General Practice Research Database
- (2009) Vasilisa Sazonov et al. ATHEROSCLEROSIS
- Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis
- (2009) Eric Bruckert et al. ATHEROSCLEROSIS
- Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)
- (2009) PAUL M. RIDKER JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial
- (2009) Paul M Ridker et al. LANCET
- After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study: Implications for Fenofibrate
- (2008) Frank M. Sacks AMERICAN JOURNAL OF CARDIOLOGY
- Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib and Off-Target Toxicity
- (2008) Menno Vergeer et al. CIRCULATION
- Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial
- (2008) Michael Miller et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis
- (2008) LANCET
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
- (2008) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Is There a Role for Fibrates in the Management of Dyslipidemia in the Metabolic Syndrome?
- (2007) Philip J. Barter et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More